The Finnish company’s endometriosis candidate could offer a better safety profile and be the first drug to address disease progression, Organon claims. Q3 revenues declined slightly due to pandemic, generic competition.
Organon Continues Building Women’s Health Portfolio With Forendo Buyout
Spotlight: Operating under the phrase “Grow and prosper,” the Doris A.Read More
Irving-based Biote is a hormone optimization company that offers patients personalized hormone therapy and clinical-grade nutraceuticals.Read More